Determinants of response to neoadjuvant chemotherapy for esophageal cancer Using 18F-fluorodeoxiglucose positron emission tomography ( 18F-FDG-PET)

Hiroshi Miyata, Makoto Yamasaki, Tsuyoshi Takahashi, Kohei Murakami, Koji Tanaka, Kurokawa Yukinori, Kiyokazu Nakajima, Shuji Takiguchi, Eiichi Morii, Jun Hatazawa, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: 18F-FDG-PET is potentially useful for evaluating response to neoadjuvant therapy for esophageal cancer. However, the optimal 18F-FDG-PET parameter for evaluating the response to therapy and survival has not been established. This study aimed to select the best of the two parameters of fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET): decreased ratio of maximal standardized uptake (SUV max-DR) or absolute value of posttreatment SUVmax (post-SUVmax), in predicting response and survival of patients with esophageal cancer who underwent neoadjuvant chemotherapy. Methods: The study subjects were 211 consecutive patients with esophageal cancer who received neoadjuvant chemotherapy followed by surgery. 18F-FDG-PET was performed before and 2-3 weeks after completion of neoadjuvant chemotherapy in assessment with pretreatment SUVmax (pre-SUVmax), post-SUVmax and SUVmax-DR. Results: The mean SUV max decreased during neoadjuvant chemotherapy from 11.4 to 5.8, and the mean SUVmax-DR was 49.4 %. Both post-SUVmax and SUVmax-DR correlated significantly with pathological response, although neither post-SUVmax nor SUVmax-DR could distinguish pathological complete response from pathological good response. The 5-year survival rate was significantly higher in patients with SUV max-DR of >50 % than those with <50 % (56.5 vs. 39.6 %, p = 0.0137), and also significantly higher in patients with post-SUVmax of <3.5 than those with >3.5 (62.2 vs. 35.1 %, p < 0.0001). Multivariate analysis identified post-SUVmax value, but not SUV max-DR, as an independent prognostic factor in patients who underwent neoadjuvant chemotherapy. Conclusions: Post-SUVmax is more useful for predicting survival of patients with esophageal cancer who undergo neoadjuvant therapy followed by surgery, although both SUVmax-DR and post-SUVmax equally correlate with pathological response.

Original languageEnglish
Pages (from-to)575-582
Number of pages8
JournalAnnals of Surgical Oncology
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 1 2014
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Positron-Emission Tomography
Drug Therapy
Neoadjuvant Therapy
Survival
Fluorodeoxyglucose F18
Multivariate Analysis
Survival Rate
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Determinants of response to neoadjuvant chemotherapy for esophageal cancer Using 18F-fluorodeoxiglucose positron emission tomography ( 18F-FDG-PET). / Miyata, Hiroshi; Yamasaki, Makoto; Takahashi, Tsuyoshi; Murakami, Kohei; Tanaka, Koji; Yukinori, Kurokawa; Nakajima, Kiyokazu; Takiguchi, Shuji; Morii, Eiichi; Hatazawa, Jun; Mori, Masaki; Doki, Yuichiro.

In: Annals of Surgical Oncology, Vol. 21, No. 2, 01.02.2014, p. 575-582.

Research output: Contribution to journalArticle

Miyata, H, Yamasaki, M, Takahashi, T, Murakami, K, Tanaka, K, Yukinori, K, Nakajima, K, Takiguchi, S, Morii, E, Hatazawa, J, Mori, M & Doki, Y 2014, 'Determinants of response to neoadjuvant chemotherapy for esophageal cancer Using 18F-fluorodeoxiglucose positron emission tomography ( 18F-FDG-PET)', Annals of Surgical Oncology, vol. 21, no. 2, pp. 575-582. https://doi.org/10.1245/s10434-013-3343-5
Miyata, Hiroshi ; Yamasaki, Makoto ; Takahashi, Tsuyoshi ; Murakami, Kohei ; Tanaka, Koji ; Yukinori, Kurokawa ; Nakajima, Kiyokazu ; Takiguchi, Shuji ; Morii, Eiichi ; Hatazawa, Jun ; Mori, Masaki ; Doki, Yuichiro. / Determinants of response to neoadjuvant chemotherapy for esophageal cancer Using 18F-fluorodeoxiglucose positron emission tomography ( 18F-FDG-PET). In: Annals of Surgical Oncology. 2014 ; Vol. 21, No. 2. pp. 575-582.
@article{66c54828bccb4365b0c1088aa3655535,
title = "Determinants of response to neoadjuvant chemotherapy for esophageal cancer Using 18F-fluorodeoxiglucose positron emission tomography ( 18F-FDG-PET)",
abstract = "Background: 18F-FDG-PET is potentially useful for evaluating response to neoadjuvant therapy for esophageal cancer. However, the optimal 18F-FDG-PET parameter for evaluating the response to therapy and survival has not been established. This study aimed to select the best of the two parameters of fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET): decreased ratio of maximal standardized uptake (SUV max-DR) or absolute value of posttreatment SUVmax (post-SUVmax), in predicting response and survival of patients with esophageal cancer who underwent neoadjuvant chemotherapy. Methods: The study subjects were 211 consecutive patients with esophageal cancer who received neoadjuvant chemotherapy followed by surgery. 18F-FDG-PET was performed before and 2-3 weeks after completion of neoadjuvant chemotherapy in assessment with pretreatment SUVmax (pre-SUVmax), post-SUVmax and SUVmax-DR. Results: The mean SUV max decreased during neoadjuvant chemotherapy from 11.4 to 5.8, and the mean SUVmax-DR was 49.4 {\%}. Both post-SUVmax and SUVmax-DR correlated significantly with pathological response, although neither post-SUVmax nor SUVmax-DR could distinguish pathological complete response from pathological good response. The 5-year survival rate was significantly higher in patients with SUV max-DR of >50 {\%} than those with <50 {\%} (56.5 vs. 39.6 {\%}, p = 0.0137), and also significantly higher in patients with post-SUVmax of <3.5 than those with >3.5 (62.2 vs. 35.1 {\%}, p < 0.0001). Multivariate analysis identified post-SUVmax value, but not SUV max-DR, as an independent prognostic factor in patients who underwent neoadjuvant chemotherapy. Conclusions: Post-SUVmax is more useful for predicting survival of patients with esophageal cancer who undergo neoadjuvant therapy followed by surgery, although both SUVmax-DR and post-SUVmax equally correlate with pathological response.",
author = "Hiroshi Miyata and Makoto Yamasaki and Tsuyoshi Takahashi and Kohei Murakami and Koji Tanaka and Kurokawa Yukinori and Kiyokazu Nakajima and Shuji Takiguchi and Eiichi Morii and Jun Hatazawa and Masaki Mori and Yuichiro Doki",
year = "2014",
month = "2",
day = "1",
doi = "10.1245/s10434-013-3343-5",
language = "English",
volume = "21",
pages = "575--582",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Determinants of response to neoadjuvant chemotherapy for esophageal cancer Using 18F-fluorodeoxiglucose positron emission tomography ( 18F-FDG-PET)

AU - Miyata, Hiroshi

AU - Yamasaki, Makoto

AU - Takahashi, Tsuyoshi

AU - Murakami, Kohei

AU - Tanaka, Koji

AU - Yukinori, Kurokawa

AU - Nakajima, Kiyokazu

AU - Takiguchi, Shuji

AU - Morii, Eiichi

AU - Hatazawa, Jun

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Background: 18F-FDG-PET is potentially useful for evaluating response to neoadjuvant therapy for esophageal cancer. However, the optimal 18F-FDG-PET parameter for evaluating the response to therapy and survival has not been established. This study aimed to select the best of the two parameters of fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET): decreased ratio of maximal standardized uptake (SUV max-DR) or absolute value of posttreatment SUVmax (post-SUVmax), in predicting response and survival of patients with esophageal cancer who underwent neoadjuvant chemotherapy. Methods: The study subjects were 211 consecutive patients with esophageal cancer who received neoadjuvant chemotherapy followed by surgery. 18F-FDG-PET was performed before and 2-3 weeks after completion of neoadjuvant chemotherapy in assessment with pretreatment SUVmax (pre-SUVmax), post-SUVmax and SUVmax-DR. Results: The mean SUV max decreased during neoadjuvant chemotherapy from 11.4 to 5.8, and the mean SUVmax-DR was 49.4 %. Both post-SUVmax and SUVmax-DR correlated significantly with pathological response, although neither post-SUVmax nor SUVmax-DR could distinguish pathological complete response from pathological good response. The 5-year survival rate was significantly higher in patients with SUV max-DR of >50 % than those with <50 % (56.5 vs. 39.6 %, p = 0.0137), and also significantly higher in patients with post-SUVmax of <3.5 than those with >3.5 (62.2 vs. 35.1 %, p < 0.0001). Multivariate analysis identified post-SUVmax value, but not SUV max-DR, as an independent prognostic factor in patients who underwent neoadjuvant chemotherapy. Conclusions: Post-SUVmax is more useful for predicting survival of patients with esophageal cancer who undergo neoadjuvant therapy followed by surgery, although both SUVmax-DR and post-SUVmax equally correlate with pathological response.

AB - Background: 18F-FDG-PET is potentially useful for evaluating response to neoadjuvant therapy for esophageal cancer. However, the optimal 18F-FDG-PET parameter for evaluating the response to therapy and survival has not been established. This study aimed to select the best of the two parameters of fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET): decreased ratio of maximal standardized uptake (SUV max-DR) or absolute value of posttreatment SUVmax (post-SUVmax), in predicting response and survival of patients with esophageal cancer who underwent neoadjuvant chemotherapy. Methods: The study subjects were 211 consecutive patients with esophageal cancer who received neoadjuvant chemotherapy followed by surgery. 18F-FDG-PET was performed before and 2-3 weeks after completion of neoadjuvant chemotherapy in assessment with pretreatment SUVmax (pre-SUVmax), post-SUVmax and SUVmax-DR. Results: The mean SUV max decreased during neoadjuvant chemotherapy from 11.4 to 5.8, and the mean SUVmax-DR was 49.4 %. Both post-SUVmax and SUVmax-DR correlated significantly with pathological response, although neither post-SUVmax nor SUVmax-DR could distinguish pathological complete response from pathological good response. The 5-year survival rate was significantly higher in patients with SUV max-DR of >50 % than those with <50 % (56.5 vs. 39.6 %, p = 0.0137), and also significantly higher in patients with post-SUVmax of <3.5 than those with >3.5 (62.2 vs. 35.1 %, p < 0.0001). Multivariate analysis identified post-SUVmax value, but not SUV max-DR, as an independent prognostic factor in patients who underwent neoadjuvant chemotherapy. Conclusions: Post-SUVmax is more useful for predicting survival of patients with esophageal cancer who undergo neoadjuvant therapy followed by surgery, although both SUVmax-DR and post-SUVmax equally correlate with pathological response.

UR - http://www.scopus.com/inward/record.url?scp=84896733347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896733347&partnerID=8YFLogxK

U2 - 10.1245/s10434-013-3343-5

DO - 10.1245/s10434-013-3343-5

M3 - Article

C2 - 24201746

AN - SCOPUS:84896733347

VL - 21

SP - 575

EP - 582

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -